Azithromycin for Critical Asthma - Pediatrics
Trial statusRecruiting
Trial phasePhase 2, Phase 3
Trial typeInterventional
Biological sexAll
Age3-17
SponsorJohns Hopkins All Children's Hospital
About this trial
The CR-AZI Study will assess the immunomodulatory effects of Azithromycin for pediatric Critical Asthma.
Eligibility criteria
Qualifiers
Age 3-17 years
Admission to the PICU
Primary diagnosis of critical asthma
Prescription for continuous inhaled beta-agonist therapy and/or intravenous (IV) beta-agonist therapy
Disqualifiers
Critical Congenital Heart Disease Unrepaired
Tracheostomy Dependence at Admission
Ongoing Exposure to Azithromycin or Macrolide Antibiotics for any indication
Past Medical History of Prolonged QT Syndrome or Arrhythmias
Trial design
Treatments tested in this trial
- Azithromycin
Treatment groups
100 Participants
are divided into 2 treatment groupsLocations
1Johns Hopkins All Children's Hospital33701, St. PetersburgFlorida, United States
Sponsors and collaborators
Johns Hopkins All Children's Hospital
Lead sponsor
Source ClinicalTrials.gov